Please Wait a Moment
X

Articles

21Sep

Reminder-Bio-Rad Geenius HIV 1/2 Implemented

21 Sep, 2020 | Return|

CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- August 8th Update

CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...

Read More >

Join us for a Babesia webinar!

As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...

Read More >

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >

National Blood Donor Month – January 2020

That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...

Read More >

Renewed NYSDOH licenses now available on the website

As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....

Read More >

FDA announces withdrawal of Guidance for ZIKV Testing

We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...

Read More >